Methylation Analyses Reveal Promoter Hypermethylation as a Rare Cause of “Second Hit” in Germline BRCA1-Associated Pancreatic Ductal Adenocarcinoma-Reference-Cited by-同舟云学术

Methylation Analyses Reveal Promoter Hypermethylation as a Rare Cause of “Second Hit” in Germline BRCA1-Associated Pancreatic Ductal Adenocarcinoma

Published:2022-09-30 Issue:6 Volume:26 Page:645-653
ISSN:1177-1062
Container-title:Molecular Diagnosis & Therapy
language:en
Short-container-title:Mol Diagn Ther

Author:

Zheng-Lin Binbin,Rainone Michael,Varghese Anna M.,Yu Kenneth H.,Park Wungki,Berger Michael,Mehine Miika,Chou Joanne,Capanu Marinela,Mandelker Diana,Stadler Zsofia K.,Birsoy Ozge,Jairam Sowmya,Yang Ciyu,Li Yirong,Wong Donna,Benhamida Jamal K,Ladanyi Marc,Zhang Liying,O’Reilly Eileen M.^ORCID

Funder

NCI/NIH

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology,Genetics,Molecular Medicine,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40291-022-00614-1.pdf

Reference34 articles.

1. Rahib L, et al. Estimated projection of US cancer incidence and death to 2040. JAMA Netw Open. 2021;4(4): e214708.

2. Park W, Chawla A, O’Reilly EM. Pancreatic cancer: a review. JAMA. 2021;326(9):851–62.

3. Golan T, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317–27.